NASDAQ:ASMB Assembly Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.19 +0.09 (+4.29%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$2.09▼$2.2050-Day Range$1.35▼$2.2752-Week Range$1.32▼$3.94Volume14,308 shsAverage Volume510,160 shsMarket Capitalization$105.59 millionP/E RatioN/ADividend YieldN/APrice Target$8.15 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Assembly Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside272.1% Upside$8.15 Price TargetShort InterestHealthy4.92% of Float Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment0.17Based on 3 Articles This WeekInsider TradingSelling Shares$7,995 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.13) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.14 out of 5 starsMedical Sector330th out of 1,427 stocksPharmaceutical Preparations Industry155th out of 680 stocks 3.3 Analyst's Opinion Consensus RatingAssembly Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.15, Assembly Biosciences has a forecasted upside of 272.1% from its current price of $2.19.Amount of Analyst CoverageAssembly Biosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.92% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 3.51%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 1.8 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Assembly Biosciences this week, compared to 9 articles on an average week.Search InterestOnly 9 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows4 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,995.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Assembly Biosciences is held by insiders.Percentage Held by Institutions52.63% of the stock of Assembly Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to grow in the coming year, from ($2.13) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Assembly Biosciences (NASDAQ:ASMB) StockAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More ASMB Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comAssembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average of $1.89June 28, 2022 | msn.comAssembly candidate dies + Bill closing ‘loophole’ to be heard + Help honor AAPI change makersJuly 4, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 27, 2022 | bizjournals.comAssembly Row names seven new tenantsJune 26, 2022 | nypost.comPro-safety groups target AOC-backed ‘defund police’ candidates in NY Assembly racesJune 26, 2022 | msn.comBrooklyn Assembly race overshadowed by candidate’s appointment of dead woman to Dem party postJune 26, 2022 | msn.comAhead of N.Y. primary, socialists and progressives set sights on incumbent Democrats in state AssemblyJune 25, 2022 | msn.comMaharashtra Assembly deputy speaker serves disqualification notice to 16 rebels MLAs, asked to reply by 27 JuneJuly 4, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 25, 2022 | nypost.comAOC Assembly pick and transit ‘champion’ racked up traffic violationsJune 22, 2022 | finance.yahoo.comAssembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022June 22, 2022 | msn.comGovernor indisposed, Assembly without full-time Speaker; Deputy Speaker to arbitrate Maha crisisJune 21, 2022 | msn.comWhat to watch for in the final week of the General AssemblyJune 21, 2022 | finance.yahoo.comAssembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022June 17, 2022 | marketwatch.comThinking about buying stock in Redbox, Acorda Therapeutics, Assembly Biosciences, Lucid Group, or Nio?June 14, 2022 | morningstar.comAssembly Biosciences Inc - Stock ChartJune 8, 2022 | finance.yahoo.comWhat Type Of Shareholders Own The Most Number of Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares?June 8, 2022 | finance.yahoo.comAssembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022June 6, 2022 | finance.yahoo.comAssembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus InfectionJune 2, 2022 | msn.comNBCUniversal signs lease with Gray Television’s Assembly Atlanta film complexJune 2, 2022 | msn.comFord to build electric vehicle at Ohio Assembly Plant in Lorain County, invest $1.5 billion in plantJune 1, 2022 | msn.comOhio General Assembly passes $3.5 billion capital budget, with $23.9 million going to Cuyahoga County – including Rock Hall, Playhouse SquareJune 1, 2022 | msn.comRivas will not become next speaker of California AssemblyMay 28, 2022 | msn.comOverburdened NYC Family Court Awaits Action from State AssemblyMay 27, 2022 | msn.comRobert Rivas said to have secured support to become Assembly SpeakerMay 14, 2022 | seekingalpha.comAssembly Biosciences GAAP EPS of -$0.48May 13, 2022 | finance.yahoo.comAssembly Biosciences Reports First Quarter 2022 Financial Results and Recent HighlightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees102Year Founded2005Company Calendar Last Earnings5/12/2022Today7/04/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$8.15 High Stock Price Forecast$14.00 Low Stock Price Forecast$3.10 Forecasted Upside/Downside+272.1%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-129,850,000.00 Net MarginsN/A Pretax Margin-2,051.12% Return on Equity-43.57% Return on Assets-38.90% Debt Debt-to-Equity RatioN/A Current Ratio12.21 Quick Ratio12.21 Sales & Book Value Annual Sales$6.25 million Price / Sales16.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book0.62Miscellaneous Outstanding Shares48,216,000Free Float46,191,000Market Cap$105.59 million OptionableOptionable Beta0.74 Social Links Assembly Biosciences Frequently Asked Questions Should I buy or sell Assembly Biosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Assembly Biosciences stock. View analyst ratings for Assembly Biosciences or view top-rated stocks. What is Assembly Biosciences' stock price forecast for 2022? 4 equities research analysts have issued 12-month price targets for Assembly Biosciences' stock. Their ASMB stock forecasts range from $3.10 to $14.00. On average, they anticipate Assembly Biosciences' share price to reach $8.15 in the next year. This suggests a possible upside of 272.1% from the stock's current price. View analysts' price targets for Assembly Biosciences or view top-rated stocks among Wall Street analysts. How has Assembly Biosciences' stock price performed in 2022? Assembly Biosciences' stock was trading at $2.33 at the start of the year. Since then, ASMB stock has decreased by 6.0% and is now trading at $2.19. View the best growth stocks for 2022 here. When is Assembly Biosciences' next earnings date? Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Assembly Biosciences. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.01. View Assembly Biosciences' earnings history. Who are Assembly Biosciences' key executives? Assembly Biosciences' management team includes the following people: Dr. John G. McHutchison A.O., FRACP, M.D., CEO, Pres & Director (Age 64, Pay $1.47M) (LinkedIn Profile)Mr. Jason A. Okazaki, Chief Operating Officer (Age 46, Pay $841.32k)Dr. William E. Delaney IV, Ph.D., Chief Scientific Officer (Age 50, Pay $637.9k)Dr. Uri A. Lopatin M.D., Co-Founder and Clinical & Scientific Advisor (Age 50)Dr. Adam Zlotnick, Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardMr. Michael P. Samar, CFO & Principal Accounting Officer (Age 49)Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR, Chief HR OfficerDr. Richard J. Colonno, Sr. Advisor (Age 72)Dr. Tharaknath Rao, Head of Microbiome Clinical Devel. & Sr. VPDr. Luisa M. Stamm M.D., Ph.D., Chief Medical Officer (Age 46) What is John McHutchison's approval rating as Assembly Biosciences' CEO? 5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees. Who are some of Assembly Biosciences' key competitors? Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Nektar Therapeutics (NKTR). View all of ASMB's competitors. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). What is Assembly Biosciences' stock symbol? Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB." How do I buy shares of Assembly Biosciences? Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Assembly Biosciences' stock price today? One share of ASMB stock can currently be purchased for approximately $2.19. How much money does Assembly Biosciences make? Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $105.59 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-129,850,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. How many employees does Assembly Biosciences have? Assembly Biosciences employs 102 workers across the globe. When was Assembly Biosciences founded? Assembly Biosciences was founded in 2005. How can I contact Assembly Biosciences? Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for Assembly Biosciences is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101. This page (NASDAQ:ASMB) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
